ONS-5010 demonstrated to be non-inferior to Lucentis at 12 weeksBLA resubmission on track for calendar Q1 2025Entered into agreements for warrant inducement transaction expected to result in up to $20 ...

Revolution Medicines, Inc. (NASDAQ:RVMD) has been making waves in the biotechnology sector with its innovative approach to ...

Sen-Jam Pharmaceutical has reported positive preliminary outcomes from its Phase II trial of SJP-002C to treat upper ...

Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release ...

Nuvalent, Inc. (NASDAQ:NUVL), a clinical-stage biopharmaceutical company with a market capitalization of $5.4 billion, has been gaining attention in the biotechnology sector for its innovative ...

The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics ...

FDA denies Vanda's Tradipitant application for gastroparesis, urging new trials for efficacy and safety. Vanda disputes the ...

In patients with cancer, HT-001, designed to address skin toxicities, elicited encouraging interim safety and efficacy ...

Concept Medical Inc., a global pioneer in innovative drug delivery technology, is proud to announce the successful enrolment ...

Palvelussamme on juuri nyt häiriö, yritäthän myöhemmin uudelleen. Pahoittelemme aiheutunutta haittaa.

Eli Lilly has received approval from the US FDA for Omvoh to treat moderately to severely active Crohn's disease in the adult ...